HomeCompareCMOPF vs NOBL

CMOPF vs NOBL: Dividend Comparison 2026

CMOPF yields 2.29% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CMOPF wins by $183.00 in total portfolio value
10 years
CMOPF
CMOPF
● Live price
2.29%
Share price
$105.00
Annual div
$2.40
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.1K
Annual income
$264.93
Full CMOPF calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — CMOPF vs NOBL

📍 CMOPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCMOPFNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CMOPF + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CMOPF pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMOPF
Annual income on $10K today (after 15% tax)
$194.28/yr
After 10yr DRIP, annual income (after tax)
$225.19/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, CMOPF beats the other by $12.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMOPF + NOBL for your $10,000?

CMOPF: 50%NOBL: 50%
100% NOBL50/50100% CMOPF
Portfolio after 10yr
$23.0K
Annual income
$257.36/yr
Blended yield
1.12%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMOPF buys
0
NOBL buys
0
No recent congressional trades found for CMOPF or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCMOPFNOBL
Forward yield2.29%2.17%
Annual dividend / share$2.40$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$23.1K$22.9K
Annual income after 10y$264.93$249.78
Total dividends collected$2.5K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: CMOPF vs NOBL ($10,000, DRIP)

YearCMOPF PortfolioCMOPF Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$10,929$228.56$10,917$217.08+$12.00CMOPF
2$11,927$233.45$11,903$221.48+$24.00CMOPF
3$13,000$238.11$12,962$225.68+$38.00CMOPF
4$14,153$242.55$14,099$229.68+$54.00CMOPF
5$15,390$246.78$15,319$233.49+$71.00CMOPF
6$16,718$250.80$16,628$237.10+$90.00CMOPF
7$18,143$254.62$18,033$240.53+$110.00CMOPF
8$19,671$258.24$19,539$243.78+$132.00CMOPF
9$21,310$261.68$21,154$246.86+$156.00CMOPF
10$23,067$264.93$22,884$249.78+$183.00CMOPF

CMOPF vs NOBL: Complete Analysis 2026

CMOPFStock

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Full CMOPF Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this CMOPF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMOPF vs SCHDCMOPF vs JEPICMOPF vs OCMOPF vs KOCMOPF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.